MIDD0301 - A first-in-class anti-inflammatory asthma drug targets GABA(A) receptors without causing systemic immune suppression.

Zahn NM, Huber AT, Mikulsky BN, Stepanski ME, Kehoe AS, Li G, Schussman M, Rashid Roni MS, Kodali R, Cook JM, Stafford DC, Steeber DA, Arnold LA

Open source

DOI: 10.1111/bcpt.13206
Published: 2019 Jul
Container: Basic & clinical pharmacology & toxicology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/bcpt.13206,
  title = {MIDD0301 - A first-in-class anti-inflammatory asthma drug targets GABA(A) receptors without causing systemic immune suppression.},
  author = {Zahn NM and Huber AT and Mikulsky BN and Stepanski ME and Kehoe AS and Li G and Schussman M and Rashid Roni MS and Kodali R and Cook JM and Stafford DC and Steeber DA and Arnold LA},
  year = {2019},
  journal = {Basic \& clinical pharmacology \& toxicology},
  doi = {10.1111/bcpt.13206},
  url = {https://doi.org/10.1111/bcpt.13206}
}

RIS

TY  - JOUR
TI  - MIDD0301 - A first-in-class anti-inflammatory asthma drug targets GABA(A) receptors without causing systemic immune suppression.
AU  - Zahn NM
AU  - Huber AT
AU  - Mikulsky BN
AU  - Stepanski ME
AU  - Kehoe AS
AU  - Li G
AU  - Schussman M
AU  - Rashid Roni MS
AU  - Kodali R
AU  - Cook JM
AU  - Stafford DC
AU  - Steeber DA
AU  - Arnold LA
PY  - 2019
JO  - Basic & clinical pharmacology & toxicology
DO  - 10.1111/bcpt.13206
UR  - https://doi.org/10.1111/bcpt.13206
ER  -

APA

NM, Z., AT, H., BN, M., ME, S., AS, K., G, L., M, S., MS, R. R., R, K., JM, C., DC, S., DA, S., & LA, A. (2019). MIDD0301 - A first-in-class anti-inflammatory asthma drug targets GABA(A) receptors without causing systemic immune suppression.. Basic & clinical pharmacology & toxicology. https://doi.org/10.1111/bcpt.13206

Source records

pubmed · retrieved 2026-09-27T08:28:35.795Z